PMID- 24759889
OWN - NLM
STAT- MEDLINE
DCOM- 20150109
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 4
DP  - 2014
TI  - Durability of a vesicular stomatitis virus-based marburg virus vaccine in 
      nonhuman primates.
PG  - e94355
LID - 10.1371/journal.pone.0094355 [doi]
LID - e94355
AB  - The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic 
      fever with high mortality in humans and nonhuman primates. A promising filovirus 
      vaccine under development is based on a recombinant vesicular stomatitis virus 
      (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the 
      VSV glycoprotein (G). These vaccines have shown 100% efficacy against filovirus 
      infection in nonhuman primates when challenge occurs 28-35 days after a single 
      injection immunization. Here, we examined the ability of a rVSV MARV-GP vaccine 
      to provide protection when challenge occurs more than a year after vaccination. 
      Cynomolgus macaques were immunized with rVSV-MARV-GP and challenged with MARV 
      approximately 14 months after vaccination. Immunization resulted in the vaccine 
      cohort of six animals having anti-MARV GP IgG throughout the pre-challenge 
      period. Following MARV challenge none of the vaccinated animals showed any signs 
      of clinical disease or viremia and all were completely protected from MARV 
      infection. Two unvaccinated control animals exhibited signs consistent with MARV 
      infection and both succumbed. Importantly, these data are the first to show 100% 
      protective efficacy against any high dose filovirus challenge beyond 8 weeks 
      after final vaccination. These findings demonstrate the durability of VSV-based 
      filovirus vaccines.
FAU - Mire, Chad E
AU  - Mire CE
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Geisbert, Joan B
AU  - Geisbert JB
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Agans, Krystle N
AU  - Agans KN
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Satterfield, Benjamin A
AU  - Satterfield BA
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Versteeg, Krista M
AU  - Versteeg KM
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Fritz, Elizabeth A
AU  - Fritz EA
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
FAU - Feldmann, Heinz
AU  - Feldmann H
AD  - Laboratory of Virology, Division of Intramural Research, National Institute of 
      Allergy and Infectious Diseases, National Institutes of Health, Hamilton, 
      Montana, United States of America.
FAU - Hensley, Lisa E
AU  - Hensley LE
AD  - Integrated Research Facility at Fort Detrick, Division of Clinical Research, 
      National Institute of Allergy and Infectious Diseases, National Institutes of 
      Health, Frederick, Maryland, United States of America.
FAU - Geisbert, Thomas W
AU  - Geisbert TW
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston, 
      Texas, United States of America; Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston, Texas, United States of America.
LA  - eng
GR  - R01 AI098817/AI/NIAID NIH HHS/United States
GR  - UC7 AI094660/AI/NIAID NIH HHS/United States
GR  - AI098817/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Ebola Vaccines)
SB  - IM
MH  - Animals
MH  - Ebola Vaccines/therapeutic use
MH  - Female
MH  - Immunity, Cellular/physiology
MH  - Immunity, Humoral/physiology
MH  - Macaca
MH  - Male
MH  - Marburg Virus Disease/immunology/prevention & control/virology
MH  - Marburgvirus/*immunology/pathogenicity
MH  - Primates
MH  - Vesicular Stomatitis/*immunology/*prevention & control/virology
MH  - Viremia/immunology/prevention & control/virology
PMC - PMC3997383
COIS- Competing Interests: CEM, JBG, KNA, BAS, KMV, EAF, and LEH have declared that no 
      competing interests exist. TWG and HF claim intellectual property regarding 
      VSV-based vaccines for the prevention and treatment of filovirus infections. This 
      does not alter the authors' adherence to PLOS ONE policies on sharing data and 
      materials.
EDAT- 2014/04/25 06:00
MHDA- 2015/01/13 06:00
PMCR- 2014/04/23
CRDT- 2014/04/25 06:00
PHST- 2013/12/16 00:00 [received]
PHST- 2014/03/14 00:00 [accepted]
PHST- 2014/04/25 06:00 [entrez]
PHST- 2014/04/25 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
PHST- 2014/04/23 00:00 [pmc-release]
AID - PONE-D-13-52211 [pii]
AID - 10.1371/journal.pone.0094355 [doi]
PST - epublish
SO  - PLoS One. 2014 Apr 23;9(4):e94355. doi: 10.1371/journal.pone.0094355. eCollection 
      2014.